Literature DB >> 2792902

Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: an important prognostic indicator.

P Rosenberg1, S Wingren, E Simonsen, O Stàl, B Risberg, B Nordenskjöld.   

Abstract

Paraffin-embedded curettage material from 120 patients with stage I and II endometrial cancer were analyzed by flow cytometry. The follow-up time in all cases was at least 5 years or until death. It was possible to determine DNA ploidy in 111 cases and S-phase was also evaluated in 92/111 cases. DNA ploidy and S-phase were then compared with the FIGO grading and clinical outcome. DNA ploidy results showed that 11% of grade 1 tumors were aneuploid, 14% of grade 2, 42% of grade 3, and 85% of the cases of uterine papillary serous carcinoma (UPSC) were aneuploid. Patients with tumors that showed an S-phase fraction below 5% had a cumulative 5-year cancer mortality of 7% whereas 49% of the patients with tumors having S-phase fraction above 10% died of their cancer. The prognostic significance of DNA and S-phase correlated fairly well with the FIGO grading as determined by a pathologist with special interest in gynecologic oncology and the DNA parameters added prognostic information independent of the FIGO grading.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2792902     DOI: 10.1016/0090-8258(89)90010-3

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

Review 1.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

2.  DNA ploidy, cell proliferation and steroid hormone receptors in endometrial hyperplasia and early adenocarcinoma.

Authors:  R Punnonen; J Mattila; T Kuoppala; T Koivula
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

3.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

4.  Genetics of endometrial cancers.

Authors:  Tsuyoshi Okuda; Akihiko Sekizawa; Yuditiya Purwosunu; Masaaki Nagatsuka; Miki Morioka; Masaki Hayashi; Takashi Okai
Journal:  Obstet Gynecol Int       Date:  2010-04-08

5.  The genomics and genetics of endometrial cancer.

Authors:  Andrea J O'Hara; Daphne W Bell
Journal:  Adv Genomics Genet       Date:  2012-03

6.  Three-dimensional nuclear telomere architecture changes during endometrial carcinoma development.

Authors:  Adrian Danescu; Sandra Herrero Gonzalez; Antonio Di Cristofano; Sabine Mai; Sabine Hombach-Klonisch
Journal:  Genes Chromosomes Cancer       Date:  2013-04-30       Impact factor: 5.006

7.  Ag-NOR protein distribution correlates with patient survival in stage I endometrial adenocarcinoma.

Authors:  D Trerè; A Cancellieri; A Perrone; G Rocchetta; G Pelusi; V Eusebi; M Derenzini
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

8.  Diosmetin enhances the sensitivity of radiotherapy by suppressing homologous recombination in endometrial cancer.

Authors:  Zhiyi Hu; Bailian Cai; Mengfei Wang; Xiaoli Wen; Anke Geng; Xiang Hu; Renhao Xue; Zhiyong Mao; Ying Jiang; Xiaoping Wan
Journal:  Cell Cycle       Date:  2020-10-16       Impact factor: 4.534

9.  Sequencing of candidate chromosome instability genes in endometrial cancers reveals somatic mutations in ESCO1, CHTF18, and MRE11A.

Authors:  Jessica C Price; Lana M Pollock; Meghan L Rudd; Sarah K Fogoros; Hassan Mohamed; Christin L Hanigan; Matthieu Le Gallo; Suiyuan Zhang; Pedro Cruz; Praveen F Cherukuri; Nancy F Hansen; Kirk J McManus; Andrew K Godwin; Dennis C Sgroi; James C Mullikin; Maria J Merino; Philip Hieter; Daphne W Bell
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

10.  DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease.

Authors:  M Karlsson; B Boeryd; J Carstensen; B Kågedal; A T Bratel; S Wingren
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.